Huimin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huimin Zhang has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Jianjun He
Department of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
18 shared publications Heyan Chen
Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
12 shared publicationsXiaoqian Li
Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
11 shared publicationsPeiling Xie
Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
10 shared publicationsYijun Li
Department of Breast Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
9 shared publicationsJunjie Liu
Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
7 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in BMC Cancer
Association of neoadjuvant subcutaneous trastuzumab with higher pathological complete response in HER2-positive breast cancer: a real-world doubly robust study
- 21 September 2026
- Published by Springer Nature in BMC Cancer
Open AccessAssociation of neoadjuvant subcutaneous trastuzumab with higher pathological complete response in HER2-positive breast cancer: a real-world doubly robust study
- Open Access
- 19 July 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Tumors >2 cm in node-negative, HER2-positive breast cancer: comparing neoadjuvant dual-targeted versus adjuvant single-targeted treatment pathways in real-world practice
Background: The optimal systemic treatment for node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer with tumors >2 cm remains unclear. De-escalation is commonly used for smaller tumors, but evidence supporting the neoadjuvant dual-targeted pathway in high tumor burden disease is limited. Objectives: To compare pathological response and exploratory disease-free survival (DFS) between the neoadjuvant dual-targeted and adjuvant single-targeted treatment pathways, focusing on tumors >2 cm. Design: Retrospective, single-center cohort study. Methods: We identified 518 consecutive patients treated from 2015 to 2023 at a tertiary academic center. In a guideline-recommended cohort ( N = 426), patients managed via the neoadjuvant dual-targeted pathway were compared with those managed via the adjuvant single-targeted pathway. Propensity scores were estimated using logistic regression and applied via overlap weighting to balance covariates. DFS was assessed using overlap-weighted Cox regression, including a tumor-size interaction (⩽2 vs >2 cm). Sensitivity analyses addressed calendar-time confounding, truncation at 24 months with bootstrapped risk differences, and surgery-date landmark analysis. Reporting followed Strengthening the Reporting of Observational Studies in Epidemiology guidelines. Results: Overlap weighting achieved good balance (all standardized mean differences 2 cm ( N = 247), the neoadjuvant dual-targeted pathway was associated with a pathological complete response rate of 56.9% (58/102) and an exploratory DFS signal (HR 0.08; 95% CI: 0.01–0.59). At 24 months, 0 versus 5 DFS events resulted in an absolute risk difference of 7.0% (95% CI: 1.1%–14.0%). Sensitivity analyses yielded consistent results, though estimates for tumors ⩽2 cm were imprecise. Conclusion: In this exploratory real-world cohort, the neoadjuvant dual-targeted treatment pathway for node-negative, HER2-positive breast cancer with tumors >2 cm was associated with high pathological response rates and an exploratory DFS signal, though sparse events and observational biases limit survival conclusions. Size-informed, risk-adapted strategies are needed. Trial registration : Not applicable.
- 19 July 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessTumors >2 cm in node-negative, HER2-positive breast cancer: comparing neoadjuvant dual-targeted versus adjuvant single-targeted treatment pathways in real-world practice
Background: The optimal systemic treatment for node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer with tumors >2 cm remains unclear. De-escalation is commonly used for smaller tumors, but evidence supporting the neoadjuvant dual-targeted pathway in high tumor burden disease is limited. Objectives: To compare pathological response and exploratory disease-free survival (DFS) between the neoadjuvant dual-targeted and adjuvant single-targeted treatment pathways, focusing on tumors >2 cm. Design: Retrospective, single-center cohort study. Methods: We identified 518 consecutive patients treated from 2015 to 2023 at a tertiary academic center. In a guideline-recommended cohort ( N = 426), patients managed via the neoadjuvant dual-targeted pathway were compared with those managed via the adjuvant single-targeted pathway. Propensity scores were estimated using logistic regression and applied via overlap weighting to balance covariates. DFS was assessed using overlap-weighted Cox regression, including a tumor-size interaction (⩽2 vs >2 cm). Sensitivity analyses addressed calendar-time confounding, truncation at 24 months with bootstrapped risk differences, and surgery-date landmark analysis. Reporting followed Strengthening the Reporting of Observational Studies in Epidemiology guidelines. Results: Overlap weighting achieved good balance (all standardized mean differences 2 cm ( N = 247), the neoadjuvant dual-targeted pathway was associated with a pathological complete response rate of 56.9% (58/102) and an exploratory DFS signal (HR 0.08; 95% CI: 0.01–0.59). At 24 months, 0 versus 5 DFS events resulted in an absolute risk difference of 7.0% (95% CI: 1.1%–14.0%). Sensitivity analyses yielded consistent results, though estimates for tumors ⩽2 cm were imprecise. Conclusion: In this exploratory real-world cohort, the neoadjuvant dual-targeted treatment pathway for node-negative, HER2-positive breast cancer with tumors >2 cm was associated with high pathological response rates and an exploratory DFS signal, though sparse events and observational biases limit survival conclusions. Size-informed, risk-adapted strategies are needed. Trial registration : Not applicable.
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (6) , 458
Development and validation of a DYX1C1- and GNAI1-based nomogram for predicting relapse in HER2-positive breast cancer treated with trastuzumab
Background: Resistance to trastuzumab and subsequent relapse remain critical challenges in human epidermal growth factor receptor 2 (HER2)-positive breast cancer management. This study aimed to develop and validate a multivariable prediction model for relapse in HER2-positive breast cancer patients treated with trastuzumab and to explore the underlying biological mechanisms of the identified biomarkers. Methods: This retrospective study utilized public gene expression profiles from the Gene Expression Omnibus (GEO) database and a clinical cohort from the First Affiliated Hospital of Xi’an Jiaotong University. The analysis included a training cohort (GSE55348, n=51), an internal validation cohort (GSE58984, n=94), and an external validation cohort (I-SPY2/GSE181574, n=127). Relapse-associated hub genes were identified via differential expression analysis and weighted gene co-expression network analysis (WGCNA). Independent predictors were determined through multivariate Cox regression to construct a nomogram for predicting 3-year relapse-free survival (RFS). Model performance was evaluated using time-dependent receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Biological mechanisms were investigated using gene set enrichment analysis (GSEA), immune infiltration analysis, and single-cell RNA sequencing (scRNA-seq). Clinical relevance was further supported by immunohistochemistry (IHC) in a pilot cohort of 12 patients. Results: DYX1C1 and GNAI1 were identified as robust, independent predictors of relapse. The constructed two-gene nomogram demonstrated excellent predictive accuracy, with an area under the curve (AUC) of 0.894 in the training cohort and 0.829 in the validation cohort. Mechanistically, DYX1C1 expression was significantly associated with an immunosuppressive tumor microenvironment (TME) characterized by reduced infiltration of B cells and CD8+ T cells, whereas GNAI1 expression correlated with stromal activation and extracellular matrix remodeling via the TGF-β signaling pathway. Single-cell analysis confirmed distinct cellular localizations of DYX1C1 in epithelial cells and GNAI1 in endothelial and mesenchymal cells. IHC analysis indicated that high protein expression of both biomarkers was associated with poor pathological complete response (pCR) to neoadjuvant therapy. Conclusions: The DYX1C1- and GNAI1-based nomogram provides a simple, accurate tool for predicting relapse in HER2-positive breast cancer treated with trastuzumab. These biomarkers are associated with distinct pro-tumorigenic TME features—DYX1C1 with immune suppression and GNAI1 with stromal activation—offering hypothesis-generating insights into therapeutic resistance.
- 1 June 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (6) , 458
Open AccessDevelopment and validation of a DYX1C1- and GNAI1-based nomogram for predicting relapse in HER2-positive breast cancer treated with trastuzumab
Background: Resistance to trastuzumab and subsequent relapse remain critical challenges in human epidermal growth factor receptor 2 (HER2)-positive breast cancer management. This study aimed to develop and validate a multivariable prediction model for relapse in HER2-positive breast cancer patients treated with trastuzumab and to explore the underlying biological mechanisms of the identified biomarkers. Methods: This retrospective study utilized public gene expression profiles from the Gene Expression Omnibus (GEO) database and a clinical cohort from the First Affiliated Hospital of Xi’an Jiaotong University. The analysis included a training cohort (GSE55348, n=51), an internal validation cohort (GSE58984, n=94), and an external validation cohort (I-SPY2/GSE181574, n=127). Relapse-associated hub genes were identified via differential expression analysis and weighted gene co-expression network analysis (WGCNA). Independent predictors were determined through multivariate Cox regression to construct a nomogram for predicting 3-year relapse-free survival (RFS). Model performance was evaluated using time-dependent receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Biological mechanisms were investigated using gene set enrichment analysis (GSEA), immune infiltration analysis, and single-cell RNA sequencing (scRNA-seq). Clinical relevance was further supported by immunohistochemistry (IHC) in a pilot cohort of 12 patients. Results: DYX1C1 and GNAI1 were identified as robust, independent predictors of relapse. The constructed two-gene nomogram demonstrated excellent predictive accuracy, with an area under the curve (AUC) of 0.894 in the training cohort and 0.829 in the validation cohort. Mechanistically, DYX1C1 expression was significantly associated with an immunosuppressive tumor microenvironment (TME) characterized by reduced infiltration of B cells and CD8+ T cells, whereas GNAI1 expression correlated with stromal activation and extracellular matrix remodeling via the TGF-β signaling pathway. Single-cell analysis confirmed distinct cellular localizations of DYX1C1 in epithelial cells and GNAI1 in endothelial and mesenchymal cells. IHC analysis indicated that high protein expression of both biomarkers was associated with poor pathological complete response (pCR) to neoadjuvant therapy. Conclusions: The DYX1C1- and GNAI1-based nomogram provides a simple, accurate tool for predicting relapse in HER2-positive breast cancer treated with trastuzumab. These biomarkers are associated with distinct pro-tumorigenic TME features—DYX1C1 with immune suppression and GNAI1 with stromal activation—offering hypothesis-generating insights into therapeutic resistance.
- Open Access
- 17 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1813674
B cell-mediated immune surveillance defines the favorable prognosis of occult breast cancer: a multi-omics study
Background: Occult breast cancer (OBC) presents with axillary lymph node (ALN) metastases without detectable primary tumor (PT) yet exhibits paradoxically favorable prognosis compared to non-occult breast cancer (non-OBC). We aimed to elucidate mechanisms underlying PT clearance by integrating multi-omics approaches to characterize the unique immune landscape. Methods: Survival outcomes were validated using the Surveillance, Epidemiology, and End Results (SEER) database (n=12,162) with propensity score matching (PSM). Molecular features were characterized via quantitative proteomics, while immune landscapes were assessed using bulk transcriptomics. Single-cell RNA sequencing (scRNA-seq) and CellChat analysis dissected cellular heterogeneity and intercellular communication within tumor microenvironment. Results: Survival analysis confirmed OBC patients have survival comparable to T1N+M0 but significantly better than T2–3N+M0 breast cancer (BC) patients. Proteomic profiling identified B cell-related pathway upregulation in OBC lymph nodes (LN). Transcriptomics revealed enriched B cell infiltration in T1 tumors correlating with improved survival. scRNA-seq further demonstrated that B cells in T1 tumors act as central hubs in intercellular communication. These cells orchestrate a robust anti-tumor response via multi-faceted secretory signals (e.g., tumor necrosis factor, TNF; B-cell activating factor, BAFF) and contact-dependent interactions (e.g., CD40; major histocompatibility complex, MHC), effectively recruiting and activating immune effectors. Conclusion: Our findings suggest that B cell-mediated immune surveillance may be a key mechanism contributing to the clearance of PT in OBC. These exploratory results underscore the potential of B cells as prognostic biomarkers and therapeutic targets in BC, pending functional validation in larger cohorts.
- 17 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1813674
Open AccessB cell-mediated immune surveillance defines the favorable prognosis of occult breast cancer: a multi-omics study
Background: Occult breast cancer (OBC) presents with axillary lymph node (ALN) metastases without detectable primary tumor (PT) yet exhibits paradoxically favorable prognosis compared to non-occult breast cancer (non-OBC). We aimed to elucidate mechanisms underlying PT clearance by integrating multi-omics approaches to characterize the unique immune landscape. Methods: Survival outcomes were validated using the Surveillance, Epidemiology, and End Results (SEER) database (n=12,162) with propensity score matching (PSM). Molecular features were characterized via quantitative proteomics, while immune landscapes were assessed using bulk transcriptomics. Single-cell RNA sequencing (scRNA-seq) and CellChat analysis dissected cellular heterogeneity and intercellular communication within tumor microenvironment. Results: Survival analysis confirmed OBC patients have survival comparable to T1N+M0 but significantly better than T2–3N+M0 breast cancer (BC) patients. Proteomic profiling identified B cell-related pathway upregulation in OBC lymph nodes (LN). Transcriptomics revealed enriched B cell infiltration in T1 tumors correlating with improved survival. scRNA-seq further demonstrated that B cells in T1 tumors act as central hubs in intercellular communication. These cells orchestrate a robust anti-tumor response via multi-faceted secretory signals (e.g., tumor necrosis factor, TNF; B-cell activating factor, BAFF) and contact-dependent interactions (e.g., CD40; major histocompatibility complex, MHC), effectively recruiting and activating immune effectors. Conclusion: Our findings suggest that B cell-mediated immune surveillance may be a key mechanism contributing to the clearance of PT in OBC. These exploratory results underscore the potential of B cells as prognostic biomarkers and therapeutic targets in BC, pending functional validation in larger cohorts.
- Open Access
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1754705
A dynamic nomogram for predicting axillary pathological complete response and its prognostic value in HER2-positive breast cancer
Background: Accurate preoperative prediction of axillary pathological complete response (apCR) following neoadjuvant therapy (NAT) is crucial for de-escalating axillary surgery in breast cancer (BC) patients. This study aimed to develop and validate a dedicated preoperative nomogram for predicting apCR in human epidermal growth factor receptor 2 (HER2)-positive BC using readily available clinical variables and to further evaluate the prognostic significance of apCR for survival outcomes within our cohort. Methods: This retrospective study enrolled 189 patients with initially node-positive, HER2-positive BC who received NAT and anti-HER2 targeted therapy. Predictors were selected via least absolute shrinkage and selection operator (LASSO) regression, and a multivariable logistic regression model was constructed and presented as a nomogram. Model performance was assessed by the area under the receiver operating characteristic curve (AUC), calibration curves, decision curve analysis (DCA), and clinical impact curve (CIC), with internal validation conducted through 1000 bootstrap resamples. The prognostic value of apCR was evaluated using Kaplan-Meier survival analysis and Cox regression. Results: In total, 115 patients (60.85%) achieved apCR in our cohort. Multivariable analysis identified three independent preoperative predictors of apCR: larger baseline axillary burden (>20 mm; OR = 0.38, 95% CI: 0.19-0.75; P = 0.005), early ultrasonographic response (complete response [CR]: OR = 4.36, 95% CI: 1.46-16.20; P = 0.014; major response [MR]: OR = 3.84, 95% CI: 1.39-12.08; P = 0.014), and receipt of intensive anti-HER2 therapy (OR = 2.03, 95% CI: 1.05-4.00; P = 0.038). The nomogram incorporating these factors demonstrated good discrimination, with an AUC of 0.735 (95% CI: 0.663-0.807), and showed good calibration and clinical utility. Furthermore, patients achieving apCR had significantly superior disease-free survival (DFS) (HR = 0.29, 95% CI: 0.09-0.92, P = 0.036). Conclusions: Our study developed and validated a preoperative nomogram that predicts apCR in HER2-positive BC by integrating three readily available clinical variables. This model demonstrates the potential to preoperatively identify candidates who may be suitable for axillary de-escalation strategies, pending future multi-center prospective validation. The established prognostic value of apCR in our cohort underscores its relevance as a critical clinical endpoint.
- 9 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1754705
Open AccessA dynamic nomogram for predicting axillary pathological complete response and its prognostic value in HER2-positive breast cancer
Background: Accurate preoperative prediction of axillary pathological complete response (apCR) following neoadjuvant therapy (NAT) is crucial for de-escalating axillary surgery in breast cancer (BC) patients. This study aimed to develop and validate a dedicated preoperative nomogram for predicting apCR in human epidermal growth factor receptor 2 (HER2)-positive BC using readily available clinical variables and to further evaluate the prognostic significance of apCR for survival outcomes within our cohort. Methods: This retrospective study enrolled 189 patients with initially node-positive, HER2-positive BC who received NAT and anti-HER2 targeted therapy. Predictors were selected via least absolute shrinkage and selection operator (LASSO) regression, and a multivariable logistic regression model was constructed and presented as a nomogram. Model performance was assessed by the area under the receiver operating characteristic curve (AUC), calibration curves, decision curve analysis (DCA), and clinical impact curve (CIC), with internal validation conducted through 1000 bootstrap resamples. The prognostic value of apCR was evaluated using Kaplan-Meier survival analysis and Cox regression. Results: In total, 115 patients (60.85%) achieved apCR in our cohort. Multivariable analysis identified three independent preoperative predictors of apCR: larger baseline axillary burden (>20 mm; OR = 0.38, 95% CI: 0.19-0.75; P = 0.005), early ultrasonographic response (complete response [CR]: OR = 4.36, 95% CI: 1.46-16.20; P = 0.014; major response [MR]: OR = 3.84, 95% CI: 1.39-12.08; P = 0.014), and receipt of intensive anti-HER2 therapy (OR = 2.03, 95% CI: 1.05-4.00; P = 0.038). The nomogram incorporating these factors demonstrated good discrimination, with an AUC of 0.735 (95% CI: 0.663-0.807), and showed good calibration and clinical utility. Furthermore, patients achieving apCR had significantly superior disease-free survival (DFS) (HR = 0.29, 95% CI: 0.09-0.92, P = 0.036). Conclusions: Our study developed and validated a preoperative nomogram that predicts apCR in HER2-positive BC by integrating three readily available clinical variables. This model demonstrates the potential to preoperatively identify candidates who may be suitable for axillary de-escalation strategies, pending future multi-center prospective validation. The established prognostic value of apCR in our cohort underscores its relevance as a critical clinical endpoint.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (2) , 105
Development and validation of a ferroptosis-related gene signature for prognostic prediction and therapeutic target identification in invasive lobular carcinoma
Background: Invasive lobular carcinoma (ILC) accounts for 15% of breast cancers and presents challenges such as chemotherapy resistance and poorer survival outcomes compared to other subtypes. While often managed similarly to invasive ductal carcinoma (IDC), ILC requires tailored approaches due to its distinct biology. Ferroptosis, an iron-dependent form of cell death, shows potential in overcoming therapeutic resistance but remains unexplored in ILC. This study aimed to identify ferroptosis-related molecular subtypes, develop a robust gene signature using machine learning, construct an integrated prognostic model, and uncover potential therapeutic targets for ILC. Methods: This study integrated data from a total of 490 patients with ILC across four datasets from The Cancer Genome Atlas (TCGA), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and Gene Expression Omnibus (GEO). The TCGA cohort was utilized for model development, while the remaining cohorts served for independent external validation. ILC samples were classified into two subtypes based on the expression levels of ferroptosis-related genes via consensus clustering. The associations between the subtypes and the tumor microenvironment (TME), biological function, and mutation were assessed. A ferroptosis-related gene signature (FRGS) was developed using the integration of machine learning. A prediction model was subsequently constructed by combining the FRGS with clinical features. Sensitivity analysis and molecular docking were used to identify potentially effective targets and drugs. Results: We identified two ferroptosis-related subtypes and found that Cluster 2 had increased immune cell infiltration. By integrating machine learning, we identified 10 hub biomarkers of ILC and developed a FRGS. The FRGS was proven to be an independent risk factor for overall survival. Combining the FRGS with clinical features, a stable and superior ILC prognostic model was constructed. Sensitivity analysis and molecular docking revealed that KLRB1 and SERPINB5 are hypothesis-generating targets and that rapamycin and AZD5582 are hypothesis-generating drug candidates for the treatment of ILC. Conclusions: By integrating multi-omics analysis, machine learning and molecular docking, we established a robust prognostic model for ILC, revealed two distinct ferroptosis-related molecular subtypes, and identified potential therapeutic targets and candidate drugs. These findings may help advance the development of personalized medicine and targeted therapies for ILC.
- 1 February 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (2) , 105
Open AccessDevelopment and validation of a ferroptosis-related gene signature for prognostic prediction and therapeutic target identification in invasive lobular carcinoma
Background: Invasive lobular carcinoma (ILC) accounts for 15% of breast cancers and presents challenges such as chemotherapy resistance and poorer survival outcomes compared to other subtypes. While often managed similarly to invasive ductal carcinoma (IDC), ILC requires tailored approaches due to its distinct biology. Ferroptosis, an iron-dependent form of cell death, shows potential in overcoming therapeutic resistance but remains unexplored in ILC. This study aimed to identify ferroptosis-related molecular subtypes, develop a robust gene signature using machine learning, construct an integrated prognostic model, and uncover potential therapeutic targets for ILC. Methods: This study integrated data from a total of 490 patients with ILC across four datasets from The Cancer Genome Atlas (TCGA), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and Gene Expression Omnibus (GEO). The TCGA cohort was utilized for model development, while the remaining cohorts served for independent external validation. ILC samples were classified into two subtypes based on the expression levels of ferroptosis-related genes via consensus clustering. The associations between the subtypes and the tumor microenvironment (TME), biological function, and mutation were assessed. A ferroptosis-related gene signature (FRGS) was developed using the integration of machine learning. A prediction model was subsequently constructed by combining the FRGS with clinical features. Sensitivity analysis and molecular docking were used to identify potentially effective targets and drugs. Results: We identified two ferroptosis-related subtypes and found that Cluster 2 had increased immune cell infiltration. By integrating machine learning, we identified 10 hub biomarkers of ILC and developed a FRGS. The FRGS was proven to be an independent risk factor for overall survival. Combining the FRGS with clinical features, a stable and superior ILC prognostic model was constructed. Sensitivity analysis and molecular docking revealed that KLRB1 and SERPINB5 are hypothesis-generating targets and that rapamycin and AZD5582 are hypothesis-generating drug candidates for the treatment of ILC. Conclusions: By integrating multi-omics analysis, machine learning and molecular docking, we established a robust prognostic model for ILC, revealed two distinct ferroptosis-related molecular subtypes, and identified potential therapeutic targets and candidate drugs. These findings may help advance the development of personalized medicine and targeted therapies for ILC.
- Open Access
- 6 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1727590
Integrative analysis of bulk and single-cell transcriptomics identifies factors related to immunosuppressive microenvironment to predict unfavorable prognosis in inflammatory breast cancer
Introduction: Inflammatory breast cancer (IBC) is a rare invasive tumor and characterized by the formation of tumor emboli within dermal lymphatic vessels. The tumor microenvironment (TME) is a key factor in IBC aggressiveness, but its heterogeneity and intercellular role remain incompletely understood. Methods: Weighted gene coexpression network analysis (WGCNA) was performed to identify immune infiltration-associated genes. We also depicted cellular communication networks and specific ligand-receptor signaling pathways using the single-cell transcriptomics analysis of IBC and non-IBC samples. Finally, we verified the expression of key proteins by immunohistochemistry. Results: Through the intersection of WGCNA module genes and differentially expressed genes between pathological complete response and residual disease samples, GZMB was identified as hub gene which is related to immune infiltration and efficacy of neoadjuvant therapy in IBC. In IBC cohort, patients with high expression of GZMB harbored more immunosuppressive cells thus showed unfavorable prognosis compared with GZMB -low expression group (pSPP1 and plasmacytoid dendritic cells were specific in IBC and associated with an immunosuppressive microenvironment in IBC. Immunohistochemical analysis suggested that protein levels of GZMB and SPP1 tended to be higher in the samples from patients with residual disease compared to the patient achieving pathological complete response, though this observation is based on an extremely small sample size. Discussion: This study identifies GZMB and SPP1 as potential immunosuppressive-related prognostic biomarkers in IBC patients, reveals the key role of plasmacytoid dendritic cells in remodeling of immunosuppressive microenvironment in IBC.
- 6 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1727590
Open AccessIntegrative analysis of bulk and single-cell transcriptomics identifies factors related to immunosuppressive microenvironment to predict unfavorable prognosis in inflammatory breast cancer
Introduction: Inflammatory breast cancer (IBC) is a rare invasive tumor and characterized by the formation of tumor emboli within dermal lymphatic vessels. The tumor microenvironment (TME) is a key factor in IBC aggressiveness, but its heterogeneity and intercellular role remain incompletely understood. Methods: Weighted gene coexpression network analysis (WGCNA) was performed to identify immune infiltration-associated genes. We also depicted cellular communication networks and specific ligand-receptor signaling pathways using the single-cell transcriptomics analysis of IBC and non-IBC samples. Finally, we verified the expression of key proteins by immunohistochemistry. Results: Through the intersection of WGCNA module genes and differentially expressed genes between pathological complete response and residual disease samples, GZMB was identified as hub gene which is related to immune infiltration and efficacy of neoadjuvant therapy in IBC. In IBC cohort, patients with high expression of GZMB harbored more immunosuppressive cells thus showed unfavorable prognosis compared with GZMB -low expression group (pSPP1 and plasmacytoid dendritic cells were specific in IBC and associated with an immunosuppressive microenvironment in IBC. Immunohistochemical analysis suggested that protein levels of GZMB and SPP1 tended to be higher in the samples from patients with residual disease compared to the patient achieving pathological complete response, though this observation is based on an extremely small sample size. Discussion: This study identifies GZMB and SPP1 as potential immunosuppressive-related prognostic biomarkers in IBC patients, reveals the key role of plasmacytoid dendritic cells in remodeling of immunosuppressive microenvironment in IBC.
- Open Access
- 12 December 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1235
Prediction model incorporating dynamic changes in serum tumor markers for evaluating the efficacy of neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study
Current prediction models for the efficacy of neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC) include only static measurements of serum tumor markers, while the dynamic measurement data of these markers have not been fully utilized. This study aimed to develop and validate a prediction model for evaluating the efficacy of NAC in BC patients on the basis of dynamic changes in CEA, CA125, and CA15-3 levels. We retrospectively screened 565 patients with BC who received NAC at our department from December 2016 to November 2021. A total of 446 patients were included and randomly divided into a training cohort (n = 312) and a test cohort (n = 134) at a 7:3 ratio. Least absolute shrinkage and selection operator (LASSO) regression with tenfold cross-validation was applied to select the most relevant features, and multivariate logistic regression was used to construct the predictive model on the basis of the selected features. The performance of the model was evaluated by the area under the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA). A nomogram integrating age, human epidermal growth factor receptor 2 (HER2) status, pre-chemotherapy levels of CEA, principal component 1 (PC1) for CEA, PC2 for CA125, and PC2 for CA15-3 was developed for the dynamic CEA&CA125&CA15-3 model. Another nomogram integrating estrogen receptor (ER) status, HER2 status, and pre-chemotherapy CEA levels was developed for the pre-chemotherapy CEA&CA125&CA15-3 model. The area under the receiver operating characteristic curve (AUC) of the dynamic model was 0.739 (95% CI 0.680-0.797) in the training cohort and 0.712 (95% CI 0.613-0.811) in the test cohort. The AUC was 0.658 (95% CI 0.593-0.722) in the training cohort and 0.715 (95% CI 0.624-0.807) in the test cohort for the pre-chemotherapy model. Compared with the pre-chemotherapy model, the dynamic model demonstrated significantly improved predictive accuracy. Our dynamic model also exhibited good predictive performance in subgroup analyses. This study developed and validated nomogram models using clinicopathological features and serum tumor marker characteristics to predict NAC efficacy in BC patients. Although the dynamic model demonstrated comparable discriminative ability (AUC) to the pre-chemotherapy model in the test cohort, it showed significantly improved performance in net reclassification. While promising, this model requires further validation in multi-center prospective studies before clinical application.
- 12 December 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1235
Open AccessPrediction model incorporating dynamic changes in serum tumor markers for evaluating the efficacy of neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study
Current prediction models for the efficacy of neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC) include only static measurements of serum tumor markers, while the dynamic measurement data of these markers have not been fully utilized. This study aimed to develop and validate a prediction model for evaluating the efficacy of NAC in BC patients on the basis of dynamic changes in CEA, CA125, and CA15-3 levels. We retrospectively screened 565 patients with BC who received NAC at our department from December 2016 to November 2021. A total of 446 patients were included and randomly divided into a training cohort (n = 312) and a test cohort (n = 134) at a 7:3 ratio. Least absolute shrinkage and selection operator (LASSO) regression with tenfold cross-validation was applied to select the most relevant features, and multivariate logistic regression was used to construct the predictive model on the basis of the selected features. The performance of the model was evaluated by the area under the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA). A nomogram integrating age, human epidermal growth factor receptor 2 (HER2) status, pre-chemotherapy levels of CEA, principal component 1 (PC1) for CEA, PC2 for CA125, and PC2 for CA15-3 was developed for the dynamic CEA&CA125&CA15-3 model. Another nomogram integrating estrogen receptor (ER) status, HER2 status, and pre-chemotherapy CEA levels was developed for the pre-chemotherapy CEA&CA125&CA15-3 model. The area under the receiver operating characteristic curve (AUC) of the dynamic model was 0.739 (95% CI 0.680-0.797) in the training cohort and 0.712 (95% CI 0.613-0.811) in the test cohort. The AUC was 0.658 (95% CI 0.593-0.722) in the training cohort and 0.715 (95% CI 0.624-0.807) in the test cohort for the pre-chemotherapy model. Compared with the pre-chemotherapy model, the dynamic model demonstrated significantly improved predictive accuracy. Our dynamic model also exhibited good predictive performance in subgroup analyses. This study developed and validated nomogram models using clinicopathological features and serum tumor marker characteristics to predict NAC efficacy in BC patients. Although the dynamic model demonstrated comparable discriminative ability (AUC) to the pre-chemotherapy model in the test cohort, it showed significantly improved performance in net reclassification. While promising, this model requires further validation in multi-center prospective studies before clinical application.
- 13 October 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (1) , 104026
Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes
- 13 October 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (1) , 104026
Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes
- Open Access
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1538523
Clinicopathological features and risk factors for local recurrence of breast phyllodes tumors: a dual-center, 12-year, retrospective study
Purpose: To clarify the risk factors of phyllodes tumor (PT) for local recurrence (LR).Methods: Data from 829 patients with pathologically confirmed benign, borderline and malignant PT of the breast, diagnosed from between 2011 to 2023, were retrieved from the electronic databases of the First Hospital of Jilin University and the First Affiliated Hospital of Xi’an Jiaotong University. Kaplan-Meier curves and Cox proportional-hazards model were conducted to determine the independent risk factors for LR in each group.Results: Of 829 PT patients, 634 (76.5%), 142 (17.1%), and 53 (6.4%) were diagnosed with benign, borderline, and malignant PT, respectively. The LR rates were 5.4%, 9.9%, 13.2%, respectively. The median patient age was 38 years and the median follow-up time was 2.8 (range, 0.2-12.1 years). Of these patients, 13 (2.1%) were diagnosed with benign bilateral PT. Multivariate analysis identified bilateral involvement as a risk factor for LR of benign PT (p=0.010). Also, univariate analysis identified young age (≤35 years, p=0.046) as an independent risk factors for LR of borderline PT. Of the patients with malignant PT, univariate analysis found that breast-conserving surgery (BCS) (p=0.008) were associated with an increased risk for LR of malignant PT.Conclusions: Bilateral PT was a risk factor for LR of benign PT, young age (≤35 years) was associated with poor prognosis of borderline PT, BCS were high risk factors for LR of malignant PT. This study identifies LR risk factors based on tumor grading, which contributes to individualized clinical risk assessment. Future research could further explore how to incorporate these factors into clinical decision-making models for PT and other soft tissue tumors.
- 26 May 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1538523
Open AccessClinicopathological features and risk factors for local recurrence of breast phyllodes tumors: a dual-center, 12-year, retrospective study
Purpose: To clarify the risk factors of phyllodes tumor (PT) for local recurrence (LR).Methods: Data from 829 patients with pathologically confirmed benign, borderline and malignant PT of the breast, diagnosed from between 2011 to 2023, were retrieved from the electronic databases of the First Hospital of Jilin University and the First Affiliated Hospital of Xi’an Jiaotong University. Kaplan-Meier curves and Cox proportional-hazards model were conducted to determine the independent risk factors for LR in each group.Results: Of 829 PT patients, 634 (76.5%), 142 (17.1%), and 53 (6.4%) were diagnosed with benign, borderline, and malignant PT, respectively. The LR rates were 5.4%, 9.9%, 13.2%, respectively. The median patient age was 38 years and the median follow-up time was 2.8 (range, 0.2-12.1 years). Of these patients, 13 (2.1%) were diagnosed with benign bilateral PT. Multivariate analysis identified bilateral involvement as a risk factor for LR of benign PT (p=0.010). Also, univariate analysis identified young age (≤35 years, p=0.046) as an independent risk factors for LR of borderline PT. Of the patients with malignant PT, univariate analysis found that breast-conserving surgery (BCS) (p=0.008) were associated with an increased risk for LR of malignant PT.Conclusions: Bilateral PT was a risk factor for LR of benign PT, young age (≤35 years) was associated with poor prognosis of borderline PT, BCS were high risk factors for LR of malignant PT. This study identifies LR risk factors based on tumor grading, which contributes to individualized clinical risk assessment. Future research could further explore how to incorporate these factors into clinical decision-making models for PT and other soft tissue tumors.